Dissatisfied with the drug price restrictions in India, Indian pharmaceutical manufacturers pay more attention to the growth opportunities of the United States

Source: China Council for the promotion of drugs 2013-05-09 this is not a big secret, international pharmaceutical companies are angry about India's revocation and veto of several drug patents But Indian pharmaceutical companies also complain about government pricing policies Indian drug series standards limit the price ceiling of reducing profits, making Indian pharmaceutical companies more keen on the US market It even depends on the US market Just look at a couple's latest quarterly results After the expiration of its exclusive right in the Lipitor generic market, Lambert laboratories' profits plummeted compared with the same period last year Rubin, on the other hand, saw a 49% jump in sales in the U.S market over the same period, which was one of the reasons for its profit surge - news that drove the share price soaring that day Rubin now accounts for 45% of his revenue in the US market Sales in the United States have reached 50% of total sales, Reuters reported Indian companies have already filed one-third of new generic applications in the US "Lambertie's domestic business accounts for only 25% of total sales, and the slow growth rate caused by pricing pressure and fierce competition makes it hard to move forward." "As a result, the company had to make more money in the global market," Parker Malik, an analyst at emkay global, told DPI In the United States, patents have been expiring in the past few years, providing generic manufacturers with the opportunity to compete with the once blockbuster brands In addition, the loss of sales due to the expiration of drug patents in 2013 will reach US $15 billion, including duloxetine, the antidepressant drug of Lilly, which expires in December Original link: http://www.finecepharma.com/story/unhappy-price-caps-home-indian-drugmakers-eye-more-us-growth/2013-05-08